[go: up one dir, main page]

WO2005060641A3 - Matrices artificielles et leur utilisation dans l'amplification par amorce unique - Google Patents

Matrices artificielles et leur utilisation dans l'amplification par amorce unique Download PDF

Info

Publication number
WO2005060641A3
WO2005060641A3 PCT/US2004/041945 US2004041945W WO2005060641A3 WO 2005060641 A3 WO2005060641 A3 WO 2005060641A3 US 2004041945 W US2004041945 W US 2004041945W WO 2005060641 A3 WO2005060641 A3 WO 2005060641A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
template
primer
anneals
predetermined sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041945
Other languages
English (en)
Other versions
WO2005060641A2 (fr
Inventor
Toshiaki Maruyama
Shana Frederickson
Katherine S Bowdish
Mark Renshaw
Ying-Chi Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to EP04814163A priority Critical patent/EP1711615A4/fr
Priority to AU2004305055A priority patent/AU2004305055B2/en
Priority to CA2549982A priority patent/CA2549982C/fr
Priority to JP2006545814A priority patent/JP2007513642A/ja
Publication of WO2005060641A2 publication Critical patent/WO2005060641A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005060641A3 publication Critical patent/WO2005060641A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Selon l'invention, on a découvert des méthodes d'amplification d'un acide nucléique consistant (a) à hybrider une amorce à une séquence d'acide nucléique de matrice, cette amorce comprenant une première partie s'hybridant à la matrice et une seconde partie de séquence prédéterminée, (b) à synthétiser un polynucléotide qui s'hybride à une partie de la matrice et qui en est complémentaire, cette partie se trouvant entre l'emplacement où la première partie de l'amorce s'hybride à la matrice et l'extrémité de la matrice, le polynucléotide possédant une première extrémité et une seconde extrémité, la première extrémité comportant l'amorce, (c) à séparer le polynucléotide synthétisé dans l'étape (b) de la matrice, (d) à hybrider un oligonucléotide niché à la seconde extrémité du polynucléotide synthétisé dans l'étape (b), l'oligonucléotide niché possédant une première partie s'hybridant à la seconde extrémité du polynucléotide et une seconde partie comprenant la même séquence prédéterminée que la seconde partie de l'amorce, (e) à étendre le polynucléotide synthétisé dans l'étape (b) en vue de l'obtention d'une partie terminale correspondante complémentaire de la séquence prédéterminée, et (f) à amplifier le polynucléotide étendu au moyen d'une amorce unique comprenant la séquence prédéterminée. Dans des modes de réalisation particulièrement utiles, ces méthodes sont utilisées pour amplifier un répertoire d'anticorps IgA.
PCT/US2004/041945 2002-09-19 2004-12-15 Matrices artificielles et leur utilisation dans l'amplification par amorce unique Ceased WO2005060641A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04814163A EP1711615A4 (fr) 2003-12-15 2004-12-15 Matrices artificielles et leur utilisation dans l'amplification par amorce unique
AU2004305055A AU2004305055B2 (en) 2002-09-19 2004-12-15 Engineered templates and their use in single primer amplification
CA2549982A CA2549982C (fr) 2003-12-15 2004-12-15 Matrices artificielles et leur utilisation dans l'amplification par amorce unique
JP2006545814A JP2007513642A (ja) 2003-12-15 2004-12-15 人工テンプレートおよび単一プライマー増幅におけるその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/737,252 US7414111B2 (en) 2001-09-19 2003-12-15 Engineered templates and their use in single primer amplification
US10/737,252 2003-12-15

Publications (2)

Publication Number Publication Date
WO2005060641A2 WO2005060641A2 (fr) 2005-07-07
WO2005060641A3 true WO2005060641A3 (fr) 2008-02-21

Family

ID=34710476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041945 Ceased WO2005060641A2 (fr) 2002-09-19 2004-12-15 Matrices artificielles et leur utilisation dans l'amplification par amorce unique

Country Status (6)

Country Link
US (1) US7414111B2 (fr)
EP (1) EP1711615A4 (fr)
JP (2) JP2007513642A (fr)
AU (1) AU2004305055B2 (fr)
CA (1) CA2549982C (fr)
WO (1) WO2005060641A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208627A1 (en) * 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
EP1677824A2 (fr) * 2003-09-18 2006-07-12 Alexion Pharmaceuticals, Inc. Sollicitation d'anticorps vers des peptides du soi dans des souris par l'immunisation avec des cellules dendritiques
JP2010507366A (ja) 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−１３受容体α１の抗体アンタゴニスト
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
SI2370466T1 (sl) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Človeška avtoprotitelesa proti alfa-sinukleinu
BR112013000341A2 (pt) * 2010-07-07 2017-09-26 Tubitak estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr)
CA3117920A1 (fr) * 2010-07-16 2012-01-19 Adimab, Llc Librairies renfermant des groupements de segmentation et leurs methodes de preparation et utilisation
LT2723379T (lt) 2011-06-23 2018-10-25 Biogen International Neuroscience Gmbh Anti-alfa sinukleiną rišančios molekulės
JP2015536672A (ja) * 2012-11-28 2015-12-24 エービーウィズ バイオ，インク． 単一プライマー増幅における使用のための遺伝子特異的なテンプレートの調製
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
JP6672310B2 (ja) 2014-09-15 2020-03-25 アブビトロ， エルエルシー ハイスループットヌクレオチドライブラリーシークエンシング
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN117512078A (zh) * 2016-09-22 2024-02-06 西格马-奥尔德里奇有限责任公司 单引物至双引物扩增子转换
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
US12065507B2 (en) * 2020-06-01 2024-08-20 University Of Kentucky Research Foundation Compounds and methods for use in connection with opioid use disorders
EP4192858A4 (fr) * 2020-08-10 2024-12-18 Integral Molecular, Inc. Méthodes et compositions pour la fabrication de bibliothèques d'anticorps et anticorps isolés à partir de celles-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595891A (en) * 1990-07-19 1997-01-21 Behringwerke Ag Method for producing a polynucleotide for use in single primer amplification
US5679512A (en) * 1992-07-31 1997-10-21 Behringwerke Ag Method for introducing defined sequences at the 3'end of polynucleotides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8108820A (pt) 1980-09-24 1982-08-24 Cetus Corp Processo e sonda de diagnostico
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
DE3381518D1 (de) 1982-01-22 1990-06-07 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (fr) 1986-03-13 1991-06-18 Henry A. Erlich Procede de detection de variations specifiques de nucleotides et de polymorphismes genetiques dans les acides nucleiques
CA1338457C (fr) 1986-08-22 1996-07-16 Henry A. Erlich Enzyme thermostable purifiee
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5508178A (en) * 1989-01-19 1996-04-16 Rose; Samuel Nucleic acid amplification using single primer
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
EP0580737B1 (fr) * 1991-04-10 2004-06-16 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
FR2724934B1 (fr) * 1994-09-26 1997-01-24 Bio Merieux Oligonucleotide chimere et son utilisation dans l'obtention de transcrits d'un acide nucleique
US5882856A (en) 1995-06-07 1999-03-16 Genzyme Corporation Universal primer sequence for multiplex DNA amplification
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
GB9817055D0 (en) 1998-08-05 1998-09-30 Medical Res Council Reverse transcription and amplification processes and primers therefore
US6465182B1 (en) 1999-04-29 2002-10-15 The Regents Of The University Of California Comparative fluorescence hybridization to oligonucleotide microarrays
JP2003505034A (ja) 1999-07-19 2003-02-12 ケンブリッジ・ユニバーシティ・テクニカル・サービシーズ・リミテッド 存在量の少ない核酸配列を増幅する方法および該方法を行うための手段
DE60026321D1 (de) * 1999-08-13 2006-04-27 Univ Yale New Haven Binär kodierte sequenzmarker
ES2447419T3 (es) * 1999-09-13 2014-03-12 Nugen Technologies, Inc. Composiciones para la amplificación isotérmica lineal de secuencias de polinucleótidos
CA2398107C (fr) 2000-01-28 2013-11-19 Althea Technologies, Inc. Procedes d'analyse de l'expression genique
JP4439262B2 (ja) * 2001-09-19 2010-03-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595891A (en) * 1990-07-19 1997-01-21 Behringwerke Ag Method for producing a polynucleotide for use in single primer amplification
US5679512A (en) * 1992-07-31 1997-10-21 Behringwerke Ag Method for introducing defined sequences at the 3'end of polynucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORENO DE ALBORAN ET AL.: "Human monoclonal Fab fragments specific for viral antigens from combinatorial IgA libraries", IMMUNOTECHNOL., vol. 1, 1995, pages 21 - 28, XP004052681 *

Also Published As

Publication number Publication date
JP2007513642A (ja) 2007-05-31
WO2005060641A2 (fr) 2005-07-07
CA2549982C (fr) 2014-07-08
EP1711615A2 (fr) 2006-10-18
EP1711615A4 (fr) 2009-05-27
JP2012157371A (ja) 2012-08-23
US7414111B2 (en) 2008-08-19
AU2004305055B2 (en) 2010-04-22
AU2004305055A1 (en) 2005-07-07
CA2549982A1 (fr) 2005-07-07
US20040175736A1 (en) 2004-09-09

Similar Documents

Publication Publication Date Title
WO2003025202A3 (fr) Matrices transgeniques et leurs utilisations dans l'amplification d'amorce unique
WO2005060641A3 (fr) Matrices artificielles et leur utilisation dans l'amplification par amorce unique
WO2006071776A3 (fr) Amplification d'arn fondee sur la ligature
WO2003008624A3 (fr) Amplification d'acides nucleiques a l'aide d'agents de synchronisation
EP1201768A3 (fr) Amplification utilisant des amorces modifiées
JP2005503802A5 (fr)
EP1256630A3 (fr) Réaction de chaíne polymérase séléctive de l'ADN de laquelle les bases de séquence sont totallement inconnus
WO2004065582A3 (fr) Amplification d'adn dans une structure en epingle a cheveux, et applications
WO2006081284A3 (fr) Procedes pour quantifier de petites molecules d'arn
WO2002101022A3 (fr) Procede d'amplification rapide de l'adn
IL131966A0 (en) An in vitro method for construction of a dna library
WO2004069849A8 (fr) Amplification d'acides nucleiques par emulsion de billes
EP1845160A4 (fr) Procedepour l'amplification d'une sequence de nucleotide
WO2004092418A3 (fr) Amplification globale effectuee avec une amorce composite amorcee de maniere aleatoire
WO2003020979A8 (fr) Procedes de preparation d'echantillons d'acide nucleique utiles pour cribler des reseaux d'adn
WO2006005074A3 (fr) Nouvelle amplification d'acides nucleiques par demarrage a chaud
WO2001094630A3 (fr) Compositions et methodes d'hybridation d'acides nucleiques a partir de jeux d'echantillons
WO2004058987A3 (fr) Amplification de l'acide nucleique
AU2001244677A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
WO2002052031A3 (fr) Amplification d'acide nucleique
DK1411122T3 (da) Fremgangsmåde til fremstilling af nukleinsyremolekyler
WO2004022770A3 (fr) Compositions et procedes de synthese d'acides nucleiques
EP1241268A3 (fr) Méthode d'amplification d'ARN
WO2003072798A3 (fr) Procede pour generer l'arn amplifie
WO2001006004A3 (fr) Procede d'amplification de sequences d'acide nucleique peu abondantes et moyens mis en oeuvre pour ce procede

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006545814

Country of ref document: JP

Ref document number: 2549982

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004305055

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2004305055

Country of ref document: AU

Date of ref document: 20041215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004305055

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004814163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004814163

Country of ref document: EP